ORLANDO, FL (February 14, 2023) — The Board of Directors of the Association for Accessible Medicines (AAM) has named as its new Chairperson, Christine Baeder, Teva Pharmaceuticals USA Chief Operating Officer for U.S. Generics and Biosimilars.
Baeder succeeds Chirag Patel, Amneal Pharmaceuticals Inc.’s Co-Founder, President, and Co-Chief Executive Officer, as AAM Board of Directors Chairman.
“The generics and biosimilars industry is an exemplar of the value that can be delivered to Americans by manufacturers, policymakers, and regulators working together. However, the industry is at a crossroads and faces real threats to its survival. No other sector helps patients afford their health care as much as generic, complex generic and biosimilar medicines, which are needed not only to create access but to free up resources to enable new and novel therapies,” said Baeder. “I am humbled that my peers have chosen me to lead at this critical time and determined to be the most forceful and effective advocate possible.”
“We are delighted to welcome Christine with her steady commitment to the industry and demonstrated leadership in her new role as AAM Board Chair,” said David Gaugh, Interim CEO of AAM. “Christine is exactly the right person to lead the membership at this time. She has the strength and focus to advance our industry’s mission to providing safe, effective, and more affordable medicines to American patients.”
Director of Communications, AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 91 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.